TTOO | T2 Biosystems, Inc. | [NASD]
Index- P/E- EPS (ttm)-14.26 Insider Own0.30% Shs Outstand24.89M Perf Week-65.47%
Market Cap2.19M Forward P/E- EPS next Y-0.58 Insider Trans-19.63% Shs Float24.70M Perf Month-71.33%
Income-62.30M PEG- EPS next Q-0.52 Inst Own6.80% Short Float / Ratio1.93% / 0.30 Perf Quarter-83.83%
Sales22.30M P/S0.10 EPS this Y21.10% Inst Trans7.66% Short Interest0.48M Perf Half Y-94.50%
Book/sh-5.34 P/B- EPS next Y64.40% ROA-149.40% Target Price- Perf Year-99.03%
Cash/sh0.44 P/C0.21 EPS next 5Y- ROE185.40% 52W Range0.10 - 15.00 Perf YTD-93.34%
Dividend- P/FCF- EPS past 5Y33.90% ROI-552.00% 52W High-99.37% Beta0.37
Dividend %- Quick Ratio1.50 Sales past 5Y36.70% Gross Margin5.40% 52W Low-3.17% ATR0.03
Employees158 Current Ratio1.90 Sales Q/Q-21.40% Oper. Margin- RSI (14)8.99 Volatility37.95% 13.64%
OptionableYes Debt/Eq- EPS Q/Q62.80% Profit Margin- Rel Volume5.29 Prev Close0.11
ShortableYes LT Debt/Eq- EarningsMay 22 BMO Payout- Avg Volume1.58M Price0.09
Recom3.00 SMA20-64.04% SMA50-74.07% SMA200-95.70% Volume8,360,587 Change-11.42%
Date Action Analyst Rating Change Price Target Change
Jan-27-21Downgrade Alliance Global Partners Buy → Neutral $2.60 → $2.40
Oct-08-20Initiated BTIG Research Buy $2.50
Nov-26-19Downgrade Janney Buy → Neutral
Aug-01-19Downgrade Alliance Global Partners Buy → Neutral
Jul-31-19Downgrade Janney Buy → Neutral
Jul-31-19Downgrade H.C. Wainwright Buy → Neutral
May-16-19Initiated Alliance Global Partners Buy $5
Mar-08-19Reiterated H.C. Wainwright Buy $14 → $11
Jun-01-18Upgrade Leerink Partners Mkt Perform → Outperform
May-30-18Reiterated H.C. Wainwright Buy $8.50 → $14
May-23-23 11:12PM
May-22-23 08:15AM
09:22AM Loading…
May-19-23 09:22AM
May-17-23 04:05PM
May-15-23 04:05PM
May-01-23 04:05PM
Apr-26-23 08:30AM
Apr-19-23 03:39PM
Apr-05-23 08:00AM
Mar-23-23 09:00AM
Mar-14-23 11:12AM
04:05PM Loading…
Mar-13-23 04:05PM
Mar-03-23 08:00AM
Feb-15-23 07:30AM
Feb-14-23 05:29AM
Feb-13-23 04:19PM
Feb-06-23 04:05PM
Feb-03-23 04:30PM
Jan-23-23 04:30PM
Dec-28-22 09:00AM
Dec-08-22 08:28AM
Nov-16-22 05:08AM
Nov-10-22 04:05PM
04:05PM Loading…
Nov-09-22 04:05PM
Nov-07-22 08:30AM
Nov-01-22 08:30AM
Oct-31-22 05:57PM
Oct-20-22 09:05AM
Oct-14-22 08:30AM
Oct-13-22 09:00AM
Oct-12-22 10:59AM
Sep-29-22 08:30AM
Sep-23-22 07:50AM
Sep-22-22 04:05PM
Sep-08-22 04:05PM
Aug-18-22 04:05PM
Aug-16-22 08:30AM
Aug-15-22 04:05PM
Aug-09-22 08:30AM
Aug-05-22 04:43PM
Jul-29-22 04:05PM
Jul-28-22 04:32PM
Jul-27-22 04:05PM
Jul-11-22 08:00AM
Jul-06-22 10:21AM
Jun-15-22 04:05PM
Jun-10-22 09:00AM
May-20-22 09:17AM
May-05-22 04:05PM
Apr-28-22 08:30AM
Apr-27-22 08:30AM
Apr-21-22 04:05PM
Apr-14-22 04:05PM
Mar-31-22 04:57PM
Mar-29-22 08:00AM
Feb-17-22 04:05PM
Feb-16-22 09:00AM
Feb-15-22 09:27AM
Feb-08-22 04:05PM
Feb-04-22 04:05PM
Feb-03-22 08:00AM
Jan-11-22 09:05AM
Dec-01-21 09:00AM
Nov-19-21 09:00AM
Nov-15-21 08:00AM
Nov-08-21 08:00AM
Nov-04-21 04:05PM
Oct-28-21 03:05PM
Oct-26-21 01:55PM
Oct-22-21 01:18PM
Oct-21-21 04:05PM
Oct-19-21 04:05PM
Oct-15-21 04:05PM
Oct-14-21 08:55AM
Oct-05-21 08:01AM
Oct-04-21 04:05PM
Sep-14-21 10:05AM
Sep-13-21 08:14AM
Sep-10-21 07:02AM
Sep-09-21 04:52PM
Sep-08-21 05:20PM
Sep-01-21 06:00PM
Aug-05-21 06:45PM
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gibbs Michael TerrenceGeneral CounselMar 28Sale0.482391156,612Apr 06 01:08 PM
Sperzel John J IIIChairman and CEOFeb 28Sale0.592,8981,71017,329Mar 09 04:00 PM
Gibbs Michael TerrenceGeneral CounselFeb 28Sale0.591,5859356,517Mar 09 04:00 PM
Sprague John MChief Financial OfficerFeb 28Sale0.591,1486777,268Mar 09 04:00 PM
Sperzel John J IIIChairman and CEOFeb 22Sale0.656,8754,46913,560Mar 09 04:00 PM
Gibbs Michael TerrenceGeneral CounselFeb 22Sale0.652,1451,3945,188Mar 09 04:00 PM
Sprague John MChief Financial OfficerFeb 22Sale0.651,5451,0045,502Mar 09 04:00 PM
Giffin Brett A.Chief Commercial OfficerFeb 22Sale0.65537349841Mar 09 04:00 PM
Giffin Brett A.Chief Commercial OfficerNov 10Sale1.791,2922,3172,253Nov 22 04:00 PM